Some of the content on this website requires JavaScript to be enabled in your web browser to function as intended. While the website is still usable without JavaScript, it should be enabled to enjoy the full interactive experience.

Skip to Main Navigation. Each navigation link will open a list of sub navigation links.

Skip to Main Content

Wyoming Drug Utilization Review (WY-DUR)|School of Pharmacy | College of Health Sciences

Contact Us

Wyoming Drug Utilization Review (WY-DUR)
Dept. 3375
1000 E. University Ave.
Laramie, WY 82070
Phone: 307-766-6750
Fax: 307-766-2953


The Wyoming Department of Health is conducting a survey concerning the use and barriers to use of 17-alpha hydroxyprogesterone in pregnant women.  If you routinely provide prenatal care for your pregnant patients, please participate in this survey.

The Draft 2016 PDL is available for review. Please submit comments before January 1, 2016.

New Drug Review: Possible P & T Committee Decisions (May 2015)

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit 

Public Comment at Meetings

 A new policy for public comment at meetings is effective December 1, 2012. 

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the February 11, 2016 P & T Committee meeting.

  • Praluent and Repatha will be approved for patients who are intolerant to statin therapy or are not at goal with a maximum dose statin for patients with heterozygous familial hypercholesterolemia.  It will be approved for patients with homozygous familial hypercholesterolemia.
  •  Brilinta will be approved for up to two years based on its new indication. 

  • Intuniv and Kapvay will be approved for children with tics, without a trial of stimulant. Other clinical criteria and trial and failure of a short-acting agent still apply.

  • Movantik will be allowed for patients with cancer or in palliative care without a trial of Amitiza.

  • Viberzi will be approved for patients with IBS-D.

  • Rexulti will be non-preferred, requiring a 30-day trial of two preferred antipsychotics prior to approval. 

Comments may be sent by email to or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY   82071.   Comments should be received prior to April 1, 2016.

P & T Committee Meeting Dates

Agenda May 11, 2016

Minutes February 11, 2016 (revised 3/22/16)

2016 Meetings

Thursday, February 11; Wednesday, May 11; Thursday, August 11; Thursday, November 10

All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.

Share This Page:

Footer Navigation

University of Wyoming Medallion
1000 E. University Ave. Laramie, WY 82071 // UW Operators (307) 766-1121 // Contact Us // Download Adobe Reader // Accessibility Accessibility information icon